July 22, 2021 8:06am
Expect a continuation of low volume trading through the seasonally-weak summer months and a more than possible correction
Pre-open indications: I’ll pass on any indications today other than -1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
I challenge the status quo to achieve what most believe is impossible, each session breaking down tactical ways to earn
Dow futures are UP +0.13% (+45 points), S&P futures are UP +0.11% (+5 point) and NASDAQ futures are 0.10% (+14 points)
U.S. stock index futures were modestly higher on Thursday
European stocks were higher
Asia-Pacific stocks were higher although COVID-19 continued to weigh on regional sentiment with markets in Japan closed for a holiday
Henry’omics:
Futures ticked higher in Wednesday's after-hours session, with investors looking to jobs data for impetus to extend a 2-day rally.
Cell and gene therapy companies can only dream: Shares of NeuroMetrix (NURO +$10.76 or +107.17%) rocketed 241% toward a two-year high on record volume, after the Massachusetts-based medical device company said its Quell transcutaneous electric nerve stimulator received "Breakthrough Designation" from the FDA to treat fibromyalgia symptoms in adults. Trading volume ballooned to 228.3 million shares, compared with the full-day average over the past 30 days of about 125,600 shares, to make the stock the biggest gainer and most actively traded on major U.S. exchanges.
Data Docket: jobless claims, which last week set a fresh pandemic-era low.
Wednesday’s evening’s recap: “whip saw behavior” … https://www.regmedinvestors.com/articles/12013
- The Nasdaq closed UP +133.08 points (+0.92%);
- The IBB closed up +0.46% and XBI closed up +0.92%;
- Sector volume was LOW with 2 of the 27-upside having higher than the 3-month average volume with very LOW volume of 1 of 7-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -1.78 points or -9.02% at 17.95;
- Wednesday’s percentage (%) of the 27-upside were +0.16% (IONS) to +6.77% (BLCM) while the 7-downside ranges from -0.20% (GBT) to -2.99% (VSTM);
Q3/21: 5 positive, 1 holiday and 9 negative close
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?
Biostage (BSTG) closed +$0.01 with 200 shares traded after Tuesday’s flat at $1.70 with 49 shares traded after Monday’s +$0.01 to $1.71 with 307 shares traded.
Question#1: WHAT is the end game or play-book for this company, it has not done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
- Call me neurotic as I feel the “Pac-Man” algorithms are “looking” for a taste of low volume upsides.
The BOTTOM LINE: Incredibly, we haven’t seen too deep percentage (%) pullback this month.
Although we firmly think the sector is alive and well, let’s not fool ourselves into thinking that earnings season won’t take its toll on share pricing.
Risk is no doubt increasing as we head into the troublesome August and September months
Volatility is still front-and-center in the sector …
I also continue to be a skeptic yet; the sustainability of Wednesday’s price change and future earnings expectations will mostly depend on management's discussion of “up-coming” clinical advances on the earnings call
A market move dragged many of the cell and gene therapy equities back to a positive upside; however, the cell and gene therapy sector is still a bit confusing as sentiment rages and fades, momentum is burped and usurped as fundamentals seem ignored.
Q2 earnings LPS (loss-per-share) release date are soon to be divulged and not positively; yet another – Sage Therapeutics (SAGE) and Alnylam Pharmaceuticals (ALNY) release “earnings” on 8/3 followed by Vericel (VCEL), MiMedx (MDXG), AxoGen (AXGN) on 8/4 and Athersys ATHX) on 8/9 – so far.
My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
